Skip to content

    OneSource Speci.

    ONESOURCEGood
    Healthcare·24 Jan 2026
    Management Summary

    OneSource Specialty Pharma's Q3 FY26 results were significantly impacted by regulatory delays for semaglutide in the Canadian market, which management described as a 'transitory' headwind. Despite the revenue and profit miss, management remains highly bullish on the long-term outlook, reiterating ambitious FY28 targets. The company is strategically pivoting from MSAs (Manufacturing Service Agreements) to CSAs (Commercial Supply Agreements) and investing heavily in capacity expansion to meet robust underlying demand.

    Highlights

    8

    • Revenue reported at ₹2,903 million, representing a 26% YoY decline due to semaglutide approval delays in Canada.

    • EBITDA stood at ₹173 million, impacted by negative operating leverage from a US$10 million revenue shortfall.

    • Adjusted PAT reported as a loss of ₹472 million; Adjusted EPS at negative ₹4.1 per share.

    • Reiterated FY28 guidance of US$400 million revenue and US$160 million EBITDA.

    • Customer advances of approximately ₹250 crores held for pre-booked capacities.

    • Committed ~US$75 million of the planned US$100 million capex for the flagship DDC site.

    • Interest costs reduced by 200 bps YoY to an effective rate of less than 9% following credit rating upgrades.

    • Biologics segment RFPs are currently 4x the levels seen at the end of the previous year.

    Concerns

    1

    • Regulatory Approval Delays

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue2,903 Mn-26%YoY
    2. 02EBITDA173 Mn
    3. 03Adjusted PAT-472 Mn
    4. 04Adjusted EPS₹-4.1
    5. 05Effective Interest Rate9%

    Segment breakdown

    DDC (Drug Device Combination)
    -10 Mn Revenue ImpactDelayed Canada Approvals Status
    Biologics
    4x RFP Funnel Growth
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Annual Revenue
    400 million
    		High
    Profitability
    EBITDA
    160 million
    		High
    Debt
    Net Debt to EBITDA
    1.5x
    		Medium
    Capex
    Flagship Site Investment
    100 million
    		High
    Capacity
    Installed Capacity
    200 million
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Regulatory Approval Delays

    Semaglutide approval in Canada pushed to Feb-May 2026 window, causing immediate revenue deferral. — Both acknowledged

    high

    Negative Operating Leverage

    Fixed cost base remains high while waiting for commercial launches, leading to soft margins in H2 FY26 and H1 FY27. — Management acknowledged

    medium

    Competitive Intensity in India

    Management notes severe competitive intensity in the Indian market, making it a non-focus area despite imminent launches. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific pricing differences between geographies (Canada vs India).

    Q&A highlights

    3

    “This is not the flagship DDC site... The plant Arun was referring to was the general injectable site, which is in Bangalore... we would need to take a shutdown.”

    Clarifies that the shutdown affects the legacy business, not the high-growth DDC/semaglutide facility.

    asked by Abdulkader Puranwala, ICICI Securities

    1 min read5 chapters

    Detailed Narrative

    01

    Semaglutide Approval Delays Impact Q3

    The quarter was defined by the 'elephant in the room': regulatory delays for semaglutide in Canada. Anchor partner Dr. Reddy's received requests for additional information, pushing expected approval to the February-May 2026 window. This resulted in a US$10 million revenue shortfall compared to the previous quarter, as the company deferred revenue until commercialization events occur.

    02

    Strategic Pivot from MSA to CSA

    Management made a deliberate strategic choice to stop accepting new MSAs (Manufacturing Service Agreements) to prioritize capacity for upcoming CSAs (Commercial Supply Agreements). While MSAs provide immediate revenue, CSAs offer significantly better economics and higher throughput. This transition, combined with approval delays, will result in 'soft' performance for the next two quarters before a major ramp-up in H2 FY27.

    03

    Biologics and Oncology Expansion

    Beyond the core DDC business, the nascent biologics segment is seeing historic highs in RFP activity, currently 4x last year's levels, aided by the U.S. Biosecure Act. Additionally, the soft gelatine business secured its first oncology asset approval (an NDA), partnered with a top 10 U.S. generic company, marking a significant expansion into specialty offerings.

    04

    Financial Strengthening and Capex

    Despite the operational hit, the balance sheet saw improvements with four notches of credit rating upgrades, leading to a 200 bps reduction in interest costs to sub-9%. The company has committed US$75 million of its US$100 million flagship site capex and doubled its workforce at that site, adding 300 FTEs to prepare for the FY27-28 scale-up.

    05

    Inventory and Working Capital Trends

    Working capital reflects a planned inventory build-up for upcoming semaglutide launches. Management emphasized that these build-ups are customer-backed by advances or firm purchase orders, with approximately ₹250 crores currently held as customer advances. They expect working capital to normalize gradually over FY27 as commercial supplies commence.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.